Insider Selling: Kura Oncology (NASDAQ:KURA) Insider Sells $834,002.78 in Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Mollie Leoni sold 84,929 shares of the company’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total value of $834,002.78. Following the sale, the insider directly owned 182,345 shares in the company, valued at $1,790,627.90. This represents a 31.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Kura Oncology Stock Up 2.3%

Shares of NASDAQ KURA opened at $10.62 on Thursday. The stock has a market cap of $942.74 million, a P/E ratio of -3.17 and a beta of 0.36. The business’s fifty day simple moving average is $9.51 and its 200-day simple moving average is $9.21. Kura Oncology, Inc. has a 12-month low of $5.45 and a 12-month high of $12.49. The company has a current ratio of 6.15, a quick ratio of 6.14 and a debt-to-equity ratio of 0.09.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.05. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%.The firm had revenue of $18.27 million during the quarter, compared to analysts’ expectations of $25.97 million. As a group, equities analysts predict that Kura Oncology, Inc. will post -3.47 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on KURA shares. CLSA set a $24.00 price objective on Kura Oncology in a research report on Thursday, June 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a report on Tuesday, April 21st. Wedbush decreased their price target on shares of Kura Oncology from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, March 6th. Wall Street Zen upgraded shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Sanford C. Bernstein set a $24.00 price target on shares of Kura Oncology in a report on Monday, June 15th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Kura Oncology presently has an average rating of “Moderate Buy” and a consensus price target of $25.46.

Institutional Trading of Kura Oncology

A number of institutional investors have recently bought and sold shares of KURA. State Street Corp boosted its position in shares of Kura Oncology by 47.5% during the 4th quarter. State Street Corp now owns 4,931,090 shares of the company’s stock worth $51,234,000 after acquiring an additional 1,587,959 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its position in shares of Kura Oncology by 101.6% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock worth $19,688,000 after acquiring an additional 1,121,228 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Kura Oncology by 111.6% during the 4th quarter. Renaissance Technologies LLC now owns 1,830,566 shares of the company’s stock worth $19,020,000 after acquiring an additional 965,256 shares in the last quarter. AQR Capital Management LLC lifted its stake in Kura Oncology by 36.6% during the fourth quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock worth $31,816,000 after purchasing an additional 820,020 shares during the last quarter. Finally, Qube Research & Technologies Ltd lifted its stake in Kura Oncology by 63.0% during the second quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock worth $11,032,000 after purchasing an additional 738,761 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.